The journey in search of the pharmacological cure for anemia that started in 1909 reached its acme in 1995–1987 with the cloning of the human EPO gene, the first clinical trial that proved the efficacy of recombinant EPO to correct the anemia of patients with chronic kidney failure and the approval of the clinical use of EPO by the FDA. This evidence concerns the gene EPO and anemia (phenotype).